ARTICLE | Clinical News

DB289: Phase II preliminary data

June 28, 2004 7:00 AM UTC

Preliminary results from a Peruvian Phase II trail in AIDS patients who failed standard therapy for PCP showed that 50 mg of DB289 given twice daily for 21 days was well tolerated. In patients receivi...